Navigation Links
Isis Pharmaceuticals and BioMed Realty Trust Celebrate Grand Opening of New R&D Facility in Carlsbad, California
Date:9/20/2011

an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2010 and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  


'/>"/>
SOURCE BioMed Realty Trust, Inc.; Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 31, 2014   Auxilium Pharmaceuticals , Inc. (NASDAQ: ... company, today announced that the Company will release results ... 7, 2014 before the opening of the U.S. financial ... that day at 8:30 a.m. ET to discuss results ... presentation slides to be used during the call will ...
(Date:7/31/2014)... , July 31, 2014  Decision ... changes brought about by the Affordable Care ... and prescribing of pharmaceutical therapies. The ACA ... beneficiaries through new regulations and expanded access ... in the health exchanges—state-based marketplaces set up ...
(Date:7/31/2014)... 2014 Touro University California,s College of Pharmacy ... the recipient of a $150,000 grant by the Joseph ... to increase research and classroom space on its campus. ... the study of health sciences, and will help us ... interests of our students," said Shelley Berkley , ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 2Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4Touro University California Garners Grant From Long Foundation 2
... -- Global Information, Inc. (GII) presents " Computed Tomography ... Market Forecasts to 2017 " by GlobalData.  ... global Computed Tomography (CT) systems market to be worth ... systems and low-dose CT systems, the market is forecast ...
... -- Physicians, Capital Investments, LLC (PCI/the Company) a leader ... is pleased to announce that Becker,s ASC Review has ... in the ASC Industry to Know." This publication recognizes ... through their work with ASC-related companies, surgery centers and ...
Cached Medicine Technology:GiiResearch.com: Computed Tomography (CT) Systems - Technological Advances and Positive Clinical Trial Evidences to Drive the Market 2GiiResearch.com: Computed Tomography (CT) Systems - Technological Advances and Positive Clinical Trial Evidences to Drive the Market 3GiiResearch.com: Computed Tomography (CT) Systems - Technological Advances and Positive Clinical Trial Evidences to Drive the Market 4Physicians' Capital Investments Announces Pedro Vergne-Marini, MD Named to Becker's ASC Review "350 People in the ASC Industry to Know" 2Physicians' Capital Investments Announces Pedro Vergne-Marini, MD Named to Becker's ASC Review "350 People in the ASC Industry to Know" 3Physicians' Capital Investments Announces Pedro Vergne-Marini, MD Named to Becker's ASC Review "350 People in the ASC Industry to Know" 4
(Date:8/1/2014)... at the Institute of Bioengineering and Nanotechnology (IBN), ... Singapore (NCCS) have co-developed the first molecular test ... in kidney cancer patients. This breakthrough was recently ... top urology journal. , According to IBN ... our expertise in molecular diagnostics and cancer research, ...
(Date:8/1/2014)... St. Christopher's Hospital for Children announced that they ... with Ed Begley Jr, airing later this year 2014, ... St. Christopher's Hospital for Children offers a wide range ... 21 years of age. With over 220 pediatric specialists, ... autism and childhood obesity. , “St. Christopher’s is ...
(Date:8/1/2014)... Jordan, Utah (PRWEB) August 01, 2014 ... company MonaVie, who completes its 500th week of paying ... since the company was founded in January 2005 total ... countries throughout the world. The company pays commissions in ... HUF, ILS, JPY, MYR, MXN, NZD, PLN, USD, SGD, ...
(Date:8/1/2014)... BellasDress has recently showcased its beautifully ... season’s gorgeous styles. The company’s lot of hot styles, ... outfits, one shoulder chiffon outfits and high low outfits. ... elegant purple prom dresses. As one of the most ... product quality. Thus, all its items are of superb ...
(Date:8/1/2014)... CentraComm, a leading managed IT security ... the Pure Storage® Authorized Reseller program. , ... experience designed to meet the rigorous resiliency, scalability, ... diverse markets, and for a variety of high ... years. , The Pure Storage FlashArray was ...
Breaking Medicine News(10 mins):Health News:Taking the guesswork out of cancer therapy 2Health News:Taking the guesswork out of cancer therapy 3Health News:Innovations with Ed Begley, Jr. to Feature St. Christopher's Hospital for Children in Upcoming Episode 2Health News:Innovations with Ed Begley, Jr. to Feature St. Christopher's Hospital for Children in Upcoming Episode 3Health News:MonaVie Records 500th Commission Week, Having Paid Out More Than $1.4B in Distributor Commissions 2Health News:BellasDress Creates Must-have Purple Prom Dresses for Prom Attendees 2Health News:CentraComm Accepts Pure Storage Authorized Reseller Partner Invitation 2Health News:CentraComm Accepts Pure Storage Authorized Reseller Partner Invitation 3
... , ... Products at E3 Expo To Show Off Consumer Market Appeal and Wellness Benefits for Gamers ... Los Angeles, CA (Vocus) ... innovative musical instruments and music software to enable people of all ages and skill levels ...
... ... of your control environment, SAS 70 reports have become a credible marketing tool to ... ... is a leading provider that specializes solely in SAS 70 readiness reviews, SAS 70 Type ...
... promising. Sorafenib is used for advanced liver and kidney ... stem cells in pancreatic cancer. The team led by ... Molecular Oncosurgery, a group of the Department of Surgery ... W. Bchler) in cooperation with the German Cancer Research ...
... with the right information, physicians can play a stronger ... drugs proven to prevent asthma attacks, according to researchers ... finds patients are more likely to routinely take inhaled ... watch over their medication use and reviewed detailed electronic ...
... ... same-day healthcare appointments online. , ... Chicago, IL (PRWEB) June 15, 2010 -- ZocDoc, the website to ... metropolitan area. The company’s move was chosen by thousands of users, who were asked ...
... ... process should not be undertaken without legal representation, urges American Residential Law Group. ... Fort Lauderdale, FL ... foreclosure not to go through the mortgage modification process without viable legal help on ...
Cached Medicine News:Health News:Beamz Announces Partnership with Dynaflex International at E3 Expo 2Health News:Beamz Announces Partnership with Dynaflex International at E3 Expo 3Health News:Beamz Announces Partnership with Dynaflex International at E3 Expo 4Health News:Can a SAS 70 Audit Create a Competitive Advantage for Your Business? 2Health News:Can a SAS 70 Audit Create a Competitive Advantage for Your Business? 3Health News:Can a SAS 70 Audit Create a Competitive Advantage for Your Business? 4Health News:New combination effective against pancreatic cancer 2Health News:Study: Getting patients to take their asthma meds 2Health News:Chicago Votes for Improved Healthcare with ZocDoc 2Health News:American Residential Law Group Urges Homeowners Not to “Go It Alone” During Mortgage Modification 2
Galaxy Single Piece PMMA Lens with UV Absorber....
Liberty Single Piece PMMA Lens with UV Absorber....
Optical implants for the replacement of the human crystalline lens in the visual correction of aphakia....
... II is a sterile nonpyrogenic, transparent viscoelastic ... II contains 12 mg/ml of high molecular ... hyaluronate dissolved in physiological saline. In the ... is 105,000 cps (105 Pa s) at ...
Medicine Products: